LT3600B - Nucleic acid fragment which codes for human proapolipoprotein a-i - Google Patents

Nucleic acid fragment which codes for human proapolipoprotein a-i Download PDF

Info

Publication number
LT3600B
LT3600B LTIP828A LTIP828A LT3600B LT 3600 B LT3600 B LT 3600B LT IP828 A LTIP828 A LT IP828A LT IP828 A LTIP828 A LT IP828A LT 3600 B LT3600 B LT 3600B
Authority
LT
Lithuania
Prior art keywords
sequence
human
dna sequence
proapo
dna
Prior art date
Application number
LTIP828A
Other languages
English (en)
Lithuanian (lt)
Inventor
Alex Bollen
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of LTIP828A publication Critical patent/LTIP828A/xx
Publication of LT3600B publication Critical patent/LT3600B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTIP828A 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i LT3600B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712540A GB8712540D0 (en) 1987-05-28 1987-05-28 Expression of human proapolipoprotein a-i

Publications (2)

Publication Number Publication Date
LTIP828A LTIP828A (en) 1995-02-27
LT3600B true LT3600B (en) 1995-12-27

Family

ID=10618034

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP828A LT3600B (en) 1987-05-28 1993-08-03 Nucleic acid fragment which codes for human proapolipoprotein a-i

Country Status (33)

Country Link
US (1) US5059528A (de)
EP (1) EP0293357B1 (de)
JP (1) JP2634193B2 (de)
KR (1) KR970000808B1 (de)
CN (1) CN1031892C (de)
AT (1) ATE89006T1 (de)
AU (1) AU615654B2 (de)
CA (1) CA1323851C (de)
CY (1) CY1809A (de)
CZ (1) CZ283648B6 (de)
DD (1) DD291093A5 (de)
DE (1) DE3880739T2 (de)
DK (1) DK175686B1 (de)
EG (1) EG19101A (de)
ES (1) ES2054878T3 (de)
FI (1) FI100056B (de)
GB (1) GB8712540D0 (de)
HK (1) HK137794A (de)
HU (1) HU204562B (de)
IE (1) IE62422B1 (de)
IL (1) IL86480A (de)
LT (1) LT3600B (de)
LV (1) LV5288A3 (de)
NO (1) NO179253C (de)
NZ (1) NZ224808A (de)
PL (1) PL158064B1 (de)
PT (1) PT87562B (de)
RU (1) RU2009198C1 (de)
SG (1) SG131594G (de)
SK (1) SK363888A3 (de)
SU (1) SU1834904A3 (de)
UA (1) UA19765A (de)
ZA (1) ZA883824B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
JP2606228B2 (ja) * 1987-09-18 1997-04-30 三菱化学株式会社 ヒトプロアポリポプロテインａ−ｉ様蛋白の産生法
EP0345155B1 (de) * 1988-05-31 1994-08-10 Mitsubishi Kasei Corporation Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind
US5846799A (en) * 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
US5460961A (en) * 1988-06-14 1995-10-24 La Region Wallonne Human myeloperoxidase and its therapeutic application
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
ATE158816T1 (de) * 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5844097A (en) * 1990-11-30 1998-12-01 Monoclonetics International, Inc. Methods for the diagnosis of peripheral nerve damage
ES2083152T3 (es) * 1990-11-30 1996-04-01 Monoclonetics Int Metodos para el diagnostico de dolores cronicos lumbares y cervicales.
GB9508618D0 (en) * 1995-04-28 1995-06-14 Applied Research Systems Therapeutic protein
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US5994061A (en) * 1995-09-29 1999-11-30 Queen's University At Kingston DNA constructs and methods for screening for increased expression of human apo AI gene
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
KR100330355B1 (ko) * 1999-06-04 2002-04-01 장인순 회전유동발생 날개를 가진 덕트형 핵연료 집합체 지지격자
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
CA2431210A1 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US7427662B2 (en) * 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1917278A2 (de) * 2005-08-26 2008-05-07 Cerenis Therapeutics Holding SA Zusammensetzungen und verfahren für die herstellung von apolipoprotein gene produkten in lactic acid bakterien
US20080293102A1 (en) * 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
CN102239260B (zh) * 2008-10-03 2017-04-12 库尔纳公司 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
EP3243504A1 (de) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Verbesserte lipidformulierung
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
SG10201911942UA (en) 2009-05-05 2020-02-27 Muthiah Manoharan Lipid compositions
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP3296398A1 (de) 2009-12-07 2018-03-21 Arbutus Biopharma Corporation Zusammensetzungen für nukleinsäurefreisetzung
EP3494963A1 (de) 2009-12-18 2019-06-12 The University of British Columbia Verfahren und zusammensetzungen zur abgabe von nukleinsäuren
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
US20130137628A1 (en) 2010-05-11 2013-05-30 Esperion Therapeutics, Inc. Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012016188A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
EP3456317B1 (de) 2011-09-27 2025-09-24 Alnylam Pharmaceuticals, Inc. Substituierte di-aliphatic pegylierte lipide
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
DK2992098T3 (da) * 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2018077159A1 (zh) * 2016-10-27 2018-05-03 中国科学院微生物研究所 氨基酸衰减子的改造方法及其在生产中的应用
ES2984286T3 (es) 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
EP3668600B1 (de) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomere
US11081113B2 (en) 2018-08-24 2021-08-03 Bright Marbles, Inc. Idea scoring for creativity tool selection
US11164065B2 (en) 2018-08-24 2021-11-02 Bright Marbles, Inc. Ideation virtual assistant tools
US11461863B2 (en) 2018-08-24 2022-10-04 Bright Marbles, Inc. Idea assessment and landscape mapping
US11189267B2 (en) 2018-08-24 2021-11-30 Bright Marbles, Inc. Intelligence-driven virtual assistant for automated idea documentation
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
MX2023012223A (es) 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
EP0186643A1 (de) 1984-11-23 1986-07-02 Région Wallonne représentée par l'Exécutif Régional Wallon Verfahren zur Herstellung von Vektorplasmiden, fähig zur Transformation von Escherichia coli-Wirtebakterien und zur Förderung und Kontrolle der Expression eines DNA-Heterologen
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587989B2 (en) * 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
GB8507833D0 (en) * 1985-03-26 1985-05-01 Biogen Nv Production of human somatomedin c
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
EP0269260A3 (de) * 1986-10-29 1988-06-22 Biotechnology Research Partners, Ltd. ApoAI-C-III-AIV, apoAII, apoB, apoCI und LDL-Rezeptor-Polymorphismus für genetischen Fingerabdruck und Atherosklerosevorhersage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6198998A (ja) 1984-10-18 1986-05-17 Matsushita Electric Ind Co Ltd 電動送風機
EP0186643A1 (de) 1984-11-23 1986-07-02 Région Wallonne représentée par l'Exécutif Régional Wallon Verfahren zur Herstellung von Vektorplasmiden, fähig zur Transformation von Escherichia coli-Wirtebakterien und zur Förderung und Kontrolle der Expression eines DNA-Heterologen
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
WO1987002062A1 (en) 1985-10-04 1987-04-09 Biotechnology Research Partners, Ltd. Recombinant apolipoproteins and methods

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
A M MAXAM AND W GILBERT: "A new method for sequencing DNA", PROC NATL ACAD SCI U S A., 1974, pages 560 - 564
BARKER W.C. ET AL.: "Evolution of lipoproteins deduced from protein sequence data", COMP BIOCHEM PHYSIOL, 1977, pages 309 - 315, XP025827046, DOI: doi:10.1016/0305-0491(77)90060-8
BREWER HB JR: "The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins", BIOCHEM BIOPHYS RES COMMUN., 1978, pages 623 - 630, XP024839665, DOI: doi:10.1016/0006-291X(78)91614-5
BROACH JR, STRATHERN JN, HICKS JB.: "Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene", GENE, pages 121 - 133
BROACH, J. R. ET AL.: "Transformation in yeast: development of a hybrid cloning vector and isolation of the CAN1 gene", GENE, 121-133
GHRAYEB J ET AL.: "Secretion cloning vectors in Escherichia coli", EMBO J., 1984, pages 2437 - 2442
J E MOTT ET AL.: "Maximizing gene expression from plasmid vectors containing the lambda PL promoter: strategies for overproducing transcription termination factor rho", PROC NATL ACAD SCI U S A., 1985, pages 88 - 92, XP001064522, DOI: doi:10.1073/pnas.82.1.88
JEFFREY H. MILLER: "Experiments in Molecular Genetics"
JEFFREY J. SEILHAMER ET AL.: "Isolation and DNA Sequence of Full-Length cDNA and of the Entire Gene for Human Apolipoprotein AIâ€"Discovery of a New Genetic Polymorphism in the apo AI Gene", DNA, 1984, pages 309 - 317
L. VILLA KOMAROFF ET AL.: "A bacterial clone synthesizing proinsulin", PROC. NATI. ACAD. SCI. USA, 1978, pages 3727 - 3731
LORENZETTI R ET AL.: "Expression of the human apolipoprotein AI gene fused to the E. coli gene for beta-galactosidase", FEBS LETT., 1986, pages 343 - 346
MALLORY JB ET AL.: "Expression and characterization of human apolipoprotein A-I in Chinese hamster ovary cells", J. BIOL. CHEM., 1987, pages 4241 - 4247
MANIATIS T. ET AL.: "Molecular cloning"
MATSUURA Y, POSSEE RD, BISHOP DH.: "Expression of the S-coded genes of lymphocytic choriomeningitis arenavirus using a baculovirus vector", J GEN VIROL., 1986, pages 1515 - 1529
P CHEUNG AND L CHAN: "Nucleotide sequence of cloned cDNA of human apolipoprotein A-I.", NUCLEIC ACIDS RES, 1983, pages 3703 - 3715
RÜTHER U, MÜLLER-HILL B.: "Easy identification of cDNA clones", EMBO J., 1983, pages 1791 - 1794

Also Published As

Publication number Publication date
CZ283648B6 (cs) 1998-05-13
LV5288A3 (lv) 1993-10-10
ATE89006T1 (de) 1993-05-15
FI882456L (fi) 1988-11-29
LTIP828A (en) 1995-02-27
PT87562B (pt) 1992-09-30
DE3880739D1 (de) 1993-06-09
SU1834904A3 (ru) 1993-08-15
JP2634193B2 (ja) 1997-07-23
CN88103118A (zh) 1988-12-14
HU204562B (en) 1992-01-28
SG131594G (en) 1995-01-13
AU1672388A (en) 1988-12-01
HK137794A (en) 1994-12-16
JPS6416589A (en) 1989-01-20
HUT47153A (en) 1989-01-30
CY1809A (en) 1995-10-20
KR970000808B1 (en) 1997-01-20
SK279166B6 (sk) 1998-07-08
EP0293357A1 (de) 1988-11-30
PT87562A (pt) 1989-05-31
IL86480A (en) 1992-08-18
SK363888A3 (en) 1998-07-08
PL272698A1 (en) 1989-03-06
PL158064B1 (pl) 1992-07-31
NO179253C (no) 1996-09-04
DD291093A5 (de) 1991-06-20
DK289688A (da) 1988-11-29
CZ363888A3 (cs) 1998-02-18
CN1031892C (zh) 1996-05-29
DE3880739T2 (de) 1993-08-19
FI100056B (fi) 1997-09-15
US5059528A (en) 1991-10-22
IL86480A0 (en) 1988-11-15
ZA883824B (en) 1989-02-22
ES2054878T3 (es) 1994-08-16
CA1323851C (en) 1993-11-02
DK289688D0 (da) 1988-05-27
GB8712540D0 (en) 1987-07-01
UA19765A (uk) 1997-12-25
EG19101A (en) 1994-09-29
AU615654B2 (en) 1991-10-10
NO882341L (no) 1988-11-29
KR880014110A (ko) 1988-12-22
IE62422B1 (en) 1995-02-08
FI882456A0 (fi) 1988-05-25
RU2009198C1 (ru) 1994-03-15
IE881597L (en) 1988-11-28
EP0293357B1 (de) 1993-05-05
DK175686B1 (da) 2005-01-17
NZ224808A (en) 1990-01-29
NO882341D0 (no) 1988-05-27
NO179253B (no) 1996-05-28

Similar Documents

Publication Publication Date Title
LT3600B (en) Nucleic acid fragment which codes for human proapolipoprotein a-i
US4743679A (en) Process for producing human epidermal growth factor and analogs thereof
Bürglin et al. The nuclear migration signal of Xenopus laevis nucleoplasmin.
Ullmann One-step purification of hybrid proteins which have β-galactosidase activity
US6331414B1 (en) Preparation of human IGF via recombinant DNA technology
JP2957974B2 (ja) エリスロポエチン活性を有するタンパク質の製造方法
CZ292703B6 (cs) Mutantní proteiny lidského interleukinu-4
JPH04503301A (ja) 合成インターロイキン―６
JP2732556B2 (ja) 生物学的に活性なｈＮＧＦ
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
PT93956A (pt) Metodo de purificacao de proteinas utilizando fusoes ctap-iii
JP2002538757A (ja) 食欲制御活性を有するポリペプチド
US5656458A (en) Expression and processing of amino terminus acetylated FGF's in yeast
US20030207795A1 (en) Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
JPS61149089A (ja) Ｄｎａ塩基配列、ポリペプチド分泌発現ベクター及び形質転換微生物
EP0441886B1 (de) EXPRESSION UND PROZESSIERUNG VON ACETYLIERTEN FGFs IN HEFEN
JPH0680697A (ja) ヒト好中球エラスターゼ阻害活性を有する天然型ポリペプチドおよびそれを含有する医薬製剤
Shibui et al. High-level expression of human proapolipoprotein AI in Escherichia coli using expression plasmids containing tandemly polymerized proapolipoprotein AI structural genes
EP0424512B1 (de) Antimetastatische peptide
Inukai et al. Effects of inserting eight amino acid residues into the major lipoprotein on its assembly in the outer membrane of Escherichia coli
DE69123242T2 (de) Physiologisch aktive Peptide, ihre Verwendung und eine Methode besagte Peptide herzustellen
EP0676412A1 (de) Gereinigtes humanes chondrocalcin, verfahren zu dessen herstellung, und verwendung davon
JPS62190083A (ja) ポリペプチド発現ベクタ−、該ベクタ−で形質転換した宿主及び該宿主によるポリペプチドの製造法
INUKAI et al. Effects of Inserting Eight Amino Acid Residues into the Major Lipoprotein on Its Assembly in the Outer Membrane of

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: 20010321 * MINISTERIE DE LA REGION WALLONNE,BE

MM9A Lapsed patents

Effective date: 20020803